The B cells are back!

Drug Discovery Today: Disease Mechanisms

Volumn 2, Issue 3, 2005, Pages 351-357

  Skogh, Thomas ^a   Kastbom, Alf ^a   Sjöwall, Christopher ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; CELL RECEPTOR; CYTOKINE; CYTOKINE RECEPTOR; FC RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIGEN ANTIBODY COMPLEX; B LYMPHOCYTE; BINDING AFFINITY; DISEASE COURSE; DRUG MECHANISM; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOPATHOGENESIS; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; OUTCOMES RESEARCH; PREDICTION; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS;

EID: 33645101719     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2005.08.007     Document Type: Review

References (50)

1. M. Krogsgaard M.M. Davis How T cells 'see' antigen Nat. Immunol. 6 2005 239-245
2. T.R. Mosmann S. Sad The expanding universe of T-cell subsets: Th1, Th2 and more Immunol. Today 17 1996 138-146
3. M. Zoulay G. Sarmay B lymphocyte signaling pathways in systemic autoimmunity: Implications for pathogenesis and treatment Arthritis Rheum. 50 2004 2730-2741
4. P. Youinou et. al. The relationship between CD5-expressing B lymphocytes and serologic abnormalities in rheumatoid arthritis patients and their relatives Arthritis Rheum. 33 1990 339-348
5. A.J. Macpherson T. Uhr Compartmentalization of the mucosal immune responses to commensal intestinal bacteria Ann. N.Y. Acad. Sci. 1029 2004 36-43
6. M. Dono et. al. The CD5+ B-cell Int. J. Biochem. Cell Biol. 36 2004 2105-2111
7. P. Youinou Y. Renaudineau The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases Thromb. Res. 114 2004 363-369
8. Y. Aydar et. al. The influence of immune complex-bearing follicular dendritic cells on the IgM response, Ig class switching, and production of high affinity IgG J. Immunol. 174 2005 5358-5366
9. A.P. Kaplan Chronic urticaria: Pathogenesis and treatment J. Allergy Clin. Immunol. 114 2004 465-474
10. H.L. Weiner Current issues in the treatment of human diseases by mucosal tolerance Ann. N.Y. Acad. Sci. 1029 2004 211-224
11. T. Skogh et. al. Gastrointestinal uptake and blood clearance of antigen in the presence of IgA antibodies Immunology 50 1983 175-180
12. K. Saito et. al. IgA-mediated inhibition of human leukocyte function by interference with Fcγ and C3b receptors Immunology 74 1991 99-106
13. C. Pasquier et. al. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: Dual role of FcRgamma ITAM Immunity 22 2005 31-42
14. B. Heyman Feedback regulation by IgG antibodies Immunol. Lett. 88 2003 157-161
15. S. Solomon et. al. The role of the complement and the FcgR system in the pathogenesis of arthritis Arthritis Res. Ther. 7 2005 129-135
16. K.A. Davies et. al. Complement deficiency and immune complex disease Springer Semin. Immunopathol. 15 1994 397-416
17. T. Skogh O. Stendahl Complement-mediated delay in immune complex clearance from the blood owing to reduced deposition outside the reticuloendothelial system Immunology 49 1982 53-59
18. D.J. Birmingham L.A. Hebert CR1 and CR1-like: The primate immune adherence receptors Immunol. Rev. 180 2001 100-111
19. T. Skogh et. al. Hepatic uptake of circulating IgG immune complexes Immunology 55 1985 585-594
20. A. Johansson et. al. Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats Hepatology 24 1996 169-175
21. J. Hed et. al. The role of negative charge in the complement-dependent dissociation of IgG-mediated aggregation Scand. J. Immunol. 21 1985 43-47
22. K. Hellsing Immune reactions in polysaccharide media. The effect of hyaluronate, chondroitin sulphate and chondroitin sulphate-protein complex on the precipitin reaction Biochem. J. 112 1969 475-481
23. T.W. Du Clos C. Mold C-reactive protein: An activator of innate immunity and a modulator of adaptive immunity Immunol. Res. 30 2004 261-277
24. A.J. Nauta et. al. A regulatory role for complement in innate immunity and autoimmunity Int. Arch. Allergy Immunol. 134 2004 310-323
25. R.M. Heuretz et. al. Native and modified C-reactive protein bind different receptors on human neutrophils Int. J. Biochem. Cell. Biol. 37 2005 320-335
26. M. Motie et. al. Binding of model soluble immune complexes to modified C-reactive protein J. Immunol. 156 1996 4435-4441
27. M.B. Pepys et. al. C-reactive protein in SLE Clin. Rheum. Dis. 8 1982 91-103
28. Molenaar et. al. Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein Arthritis Rheum. 44 2001 997-1002
29. C. Sjöwall et. al. C-reactive protein and anti-CRP autoantibodies in systemic lupus erythematosus Curr. Rheumatol. Rev. 1 2005 81-89
30. S.H. Li et. al. C-reactive protein upregulates complement-inhibitory factors in endothelial cells Circulation 109 2004 833-836
31. D.C. Roopenian et. al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostais, and fate of IgG-Fc-coupled drugs J. Immunol. 170 2003 3528-3533
32. J.V. Ravetch S. Bolland IgG Fc receptors Annu. Rev. Immunol. 19 2001 275-290
33. M. Daëron et. al. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors J. Clin. Invest. 95 1995 577-585
34. V.M. Abrahams et. al. Induction of tumor necrosis factor alpha production by adhered human monocytes: A key role for Fcgamma receptor type IIIa in rheumatoid arthritis Arthritis Rheum. 43 2000 608-616
35. 2α reigns supreme in arthritis and bone resorption Trends Immunol. 25 2004 116-119
36. S. Amigorena et. al. Type II and III receptors for immunoglobulin G (IgG) control the presentation of different T cell epitopes from single IgG-complexed antigens J. Exp. Med. 187 1998 505-515
37. A. Samuelsson et. al. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor Science 291 2001 484-486
38. A.W. Morgan et. al. FcgammaRIIIA-158V and rheumatoid arthritis: A confirmation study Rheumatology 42 2003 528-533
39. Kastbom, A. et al. (2005) The 158V polymorphism of Fc gamma receptor type IIIA in early rheumatoid arthritis: Increased susceptibility and severity in male patients (the Swedish TIRA project). Rheumatology (in press, E-pub 5 July 2005)
40. N.M. van Sorge et. al. FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy Tissue Antigens 61 2003 189-202
41. M. Feldmann et. al. The transfer of a laboratory based hypothesis to a clinically useful therapy: The development of anti-TNF therapy of rheumatoid arthritis Best Pract. Res. Clin. Rheumatol. 18 2004 59-80
42. A. Familian et. al. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis Ann. Rheum. Dis. 64 2005 1003-1008
43. G.S. Panayi B cells: A fundamental role in the pathogenesis of rheumatoid arthritis? Rheumatology 44 Suppl. 2 2005 3-7
44. M.M. O'Sullivan et. al. Complement-mediated inhibition of immune precipitation in rheumatoid vasculitis Rheumatol. Int. 10 1990 159-163
45. S. Nijenhuis et. al. Autoantibodies to citrullinated proteins in rheumatoid arthritis: Clinical performance and biochemical aspects of an RA-specific marker Clin. Chim. Acta 350 2004 17-34
46. E.R. Vossenaar et. al. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease Bioessays 25 2003 1106-1118
47. J.A. Hill et. al. Cutting edge: The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule J. Immunol. 171 2003 538-541
48. K. Forslind et. al. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: Role of antibodies to citrullinated peptides (anti-CCP) Ann. Rheum. Dis. 63 2004 1090-1095
49. E. Berglin et. al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis Arthritis Res. Ther. 6 2004 R303-R308
50. A. Kastbom et. al. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project) Ann. Rheum. Dis. 63 2004 1085-1089